Published in Heart Fail Rev on October 01, 2004
Dorsal spinal cord stimulation obtunds the capacity of intrathoracic extracardiac neurons to transduce myocardial ischemia. Am J Physiol Regul Integr Comp Physiol (2009) 1.04
The effects of aetiology on outcome in patients treated with cardiac resynchronization therapy in the CARE-HF trial. Eur Heart J (2009) 1.02
Sudden cardiac death in heart failure with preserved ejection fraction: a target for therapy? Heart Fail Rev (2016) 0.75
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med (1999) 29.32
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med (1992) 18.74
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med (1991) 16.19
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med (2003) 13.25
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med (1996) 12.77
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (1999) 11.26
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med (2003) 10.57
Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med (1987) 8.77
A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med (1991) 8.65
Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation (2001) 5.87
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet (2001) 4.65
The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med (1995) 4.61
QT dispersion and sudden unexpected death in chronic heart failure. Lancet (1994) 4.17
A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med (2001) 4.07
Short-term heart rate variability strongly predicts sudden cardiac death in chronic heart failure patients. Circulation (2003) 3.75
Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation (2002) 3.34
Clinical classification of cardiac deaths. Circulation (1982) 2.93
Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension (2001) 2.61
A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation (1994) 2.58
Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation (2000) 2.49
Aldosterone in congestive heart failure. N Engl J Med (2001) 2.46
The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation (1984) 2.45
Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. Am Heart J (1997) 2.44
Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy. Am J Cardiol (1983) 2.24
Nonsustained ventricular tachycardia in severe heart failure. Independent marker of increased mortality due to sudden death. GESICA-GEMA Investigators. Circulation (1996) 1.92
Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation (2000) 1.70
Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation (1999) 1.69
Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation (2002) 1.63
Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. Circulation (1989) 1.61
Aldosterone blunts the baroreflex response in man. Clin Sci (Lond) (1998) 1.60
A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. J Card Fail (2003) 1.60
Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators. Eur Heart J (1997) 1.54
Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study. Eur Heart J (1998) 1.52
Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. Am J Cardiol (1999) 1.48
Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction. Am Heart J (2001) 1.47
Mechanism of death and prevalence of myocardial ischemic symptoms in the terminal event after acute myocardial infarction. Am J Cardiol (1988) 1.42
Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin Sci (Lond) (2002) 1.31
Mode of death in heart failure: findings from the ATLAS trial. Heart (2003) 1.24
Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res (1997) 1.24
Pathophysiologic mechanisms of cardiac arrhythmias. Am Heart J (1983) 1.19
Effect of the angiotensin II type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension. Hypertension (2000) 1.19
Prognostic importance of the serum magnesium concentration in patients with congestive heart failure. J Am Coll Cardiol (1990) 1.15
Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure. Cardiovasc Res (2002) 1.12
Exploration of the precision of classifying sudden cardiac death. Implications for the interpretation of clinical trials. Circulation (1996) 1.11
How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart (1999) 1.08
Primary prevention of sudden cardiac death in heart failure: will the solution be shocking? J Am Coll Cardiol (1997) 1.05
Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol (1995) 0.98
Angiotensin-converting enzyme and endothelial nitric oxide synthase polymorphisms in patients with atrial fibrillation. Pacing Clin Electrophysiol (2003) 0.94
Chronic administration of aldosterone depresses baroreceptor reflex function in the dog. Hypertension (1994) 0.91
MERIT-HF mortality and morbidity data. Basic Res Cardiol (2000) 0.90
ACE inhibition improves cardiac NE uptake and attenuates sympathetic nerve terminal abnormalities in heart failure. Am J Physiol (1999) 0.90
The associations of levels of serum potassium and magnesium with ventricular premature complexes (the Framingham Heart Study). Am J Cardiol (1994) 0.89
Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. J Am Coll Cardiol (2002) 0.87
Mechanism by which quinapril improves vascular function in coronary artery disease. Am J Cardiol (1999) 0.84
Metoprolol controlled release/extended release in patients with severe heart failure: analysis of the experience in the MERIT-HF study. J Am Coll Cardiol (2001) 0.83
Aldosterone: cardiovascular assault. Am Heart J (2002) 0.83
Effect of angiotensin-converting enzyme therapy on QT interval dispersion. Am J Ther (1999) 0.82
Effect of propranolol on ventricular arrhythmia. The beta-blocker heart attack trial experience. Circulation (1983) 0.82
Significance and control of cardiac arrhythmias in patients with congestive cardiac failure. Heart Fail Rev (2002) 0.81
Arrhythmias and sudden death in heart failure. Jpn Circ J (1997) 0.80
Role of beta blockade in the treatment of myocardial ischemia. Am J Cardiol (1997) 0.80
ACE inhibitors suppress ischemia-induced arrhythmias by reducing the spatial dispersion of ventricular repolarization. Cardiology (1999) 0.79
Propranolol therapy in patients with acute myocardial infarction: the Beta-Blocker Heart Attack Trial. Circulation (1983) 0.79
Endothelial dysfunction and cardiovascular disease: the promise of blocking the renin-angiotensin system. Int J Clin Pract (2003) 0.78
Metoprolol CR/XL in postmyocardial infarction patients with chronic heart failure: experiences from MERIT-HF. Am Heart J (2003) 0.78
Angiotensin-converting enzyme inhibition after myocardial infarction: the Trandolapril Cardiac Evaluation Study. Am Heart J (1996) 0.78
Incidence of sudden cardiac death associated with coronary artery occlusion in dogs with hypertension and left ventricular hypertrophy is reduced by chronic beta-adrenergic blockade. Circulation (1990) 0.77
Exercise-induced ventricular arrhythmias in congestive heart failure and role of ACE inhibitors. J Assoc Physicians India (1998) 0.75
Effects of beta-blockade on the incidence of ventricular tachyarrhythmias during acute myocardial ischemia: experimental findings and clinical implications. Basic Res Cardiol (1990) 0.75
Anti-arrhythmic efficacy of beta-adrenergic blockade during acute ischemia in myocardium with scar. Am J Med Sci (1994) 0.75
Comparison of spirapril, isradipine, or combination in hypertensive patients with left ventricular hypertrophy: effects on LVH regression and arrhythmogenic propensity. Am J Hypertens (1998) 0.75